VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

VERTEX PHARMACEUTICALS INC / MA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$501.95+2.21 (+0.44%)

Close on Oct 19, 2026

Market cap: $128.10B
P/E (TTM): 29.2
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Vertex Pharmaceuticals Inc / Ma reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Vertex Pharmaceuticals Inc / Ma's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Vertex Pharmaceuticals Inc / Ma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Aug 24, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRTX.

Revenue growth10.2% · median 4.4%

Gross margin86.0% · median 49.6%

Operating margin38.0% · median 11.4%

Net margin35.0% · median 16.4%

Company	Revenue	Growth
REGN	$15.53B	+9.3%
VTRS	$14.74B	+4.4%
TEVA	$14.10B	-15.2%
VRTX	$12.59B	+10.2%
GMAB	–	–
ALNY	–	–

Company

Next earnings (est.): Nov 2, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 600,000
Held by institutions: 95.6%
Auditor: Ernst & Young LLP
SEC CIK: 875320

Advertisement
300 × 250